Respiratory Cancer and inhaled inorganic Arsenic in copper smeltere workers: A linear relationship with cumulative exposure that increases with concentration

Environmental Health Perspectives

Volumn 116, Issue 12, 2008, Pages 1661-1665

  Lubin, Jay H ^a   Moore, Lee E ^b   Fraumeni Jr , Joseph F ^a   Cantor, Kenneth P ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Occupational Epidemiology Branch   (United States)

Author keywords

Arsenic; Dose response relationship; Lung neoplasms; Occupational diseases

Indexed keywords

ARSENIC; COPPER; CARCINOGEN;

ARTICLE; CANCER MORTALITY; CONCENTRATION RESPONSE; FOLLOW UP; HUMAN; INDUSTRIAL WORKER; METAL INDUSTRY; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; RESPIRATORY TRACT CANCER; RISK ASSESSMENT; SMELTER; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; DOSE RESPONSE; EXPOSURE; RESPIRATORY TRACT TUMOR; UNITED STATES;

ARSENIC; CARCINOGENS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INHALATION EXPOSURE; MONTANA; OCCUPATIONAL EXPOSURE; RESPIRATORY TRACT NEOPLASMS;

EID: 58149355212     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.11515     Document Type: Article

References (47)

1. Ahsan H, Chen Y, Kibriya MG, Slavkovich V, Parvez F, Jasmine F, et al. 2007. Arsenic metabolism, genetic susceptibility, and risk of premalignant skin lesions in Bangladesh. Cancer Epidemiol Biomarkers Prev 16:1270-1278.
2. Ahsan H, Chen Y, Parvez F, Zablotska L, Argos M, Hussain I, et al. 2006. Arsenic exposure from drinking water and risk of premalignant skin lesions in Bangladesh: baseline results from the Health Effects of Arsenic Longitudinal Study. Am J Epidemiol 163:1138-1148.
3. Aposhian HV, Gurzau ES, Le XC, Gurzau A, Healy SM, Lu X, et al. 2000. Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic. Chem Res Toxicol 13:693-697.
4. Bates MN, Smith AH, Hopenhayn-Rich C. 1992. Arsenic ingestion and internal cancers: a review. Am J Epidemiol 135:462-476.
5. Breslow NE, Day NE. 1987. Statistical Methods in Cancer Research: The Analysis of Cohort Studies. Lyon, France: International Agency for Research on Cancer.
6. Cantor KP, Lubin JH. 2007. Arsenic, internal cancers, and issues in inference from studies of low-level exposures in human populations. Toxicol Appl Pharmacol 222:252-257.
7. Chen YC, Guo YLL, Su HJJ, Hsueh YM, Smith TJ, Lee MS, et al. 2003a. Arsenic methylation and skin cancer risk in southwestern Taiwan. J Occup Environ Med 45:241-248.
8. Chen YC, Su HJJ, Guo YLL, Hsueh YM, Smith TJ, Ryan LM, et al. 2003b. Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control 14:303-310.
9. Cullen WR, Reimer KJ. 1989. Arsenic speciation in the environment. Chem Rev 89:713-764.
10. Engel RR, Hopenhayn-Rich C, Receveur O, Smith AH. 1994. Vascular effects of chronic arsenic exposure: a review. Epidemiol Rev 16:184-209.
11. Enterline PE, Henderson VL, Marsh GM. 1987. Exposure to arsenic and respiratory cancer. A reanalysis. Am J Epidemiol 125:929-938.
12. Hertz-Picciotto I, Smith AH. 1993. Observations on the doseresponse curve for arsenic exposure and lung cancer. Scand J Work Environ Health 19:217-226.
13. Hopenhayn-Rich C, Biggs ML, Kalman DA, Moore LE, Smith AH. 1996a. Arsenic methylation patterns before and after changing from high to lower concentrations of arsenic in drinking water. Environ Health Perspect 104:1200-1207.
14. Hopenhayn-Rich C, Biggs ML, Smith AH, Kalman DA, Moore LE. 1996b. Methylation study of a population environmentally exposed to arsenic in drinking water. Environ Health Perspect 104:620-628.
15. Hsueh YM, Chiou HY, Huang YL, Wu WL, Huang CC, Yang MH, et al. 1997. Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol Biomarkers Prev 6:589-596.
16. International Agency for Research on Cancer. 1980. Evaluation of the Carcinogenic Risk of Some Metals and Metallic Compounds. Monogr Eval Carcinog Risk Chem Hum 23.
17. International Agency for Research on Cancer. 1987. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs, Volumes 1 to 42. Monogr Eval Carcinog Risk Chem Hum Suppl 7.
18. Karagas MR, Tosteson TD, Morris JS, Demidenko E, Mott LA, Heaney J, et al. 2004. Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire. Cancer Causes Control 15:465-472.
19. Kitchin KT, Wallace K. 2008. The role of protein binding of trivalent arsenicals in arsenic carcinogenesis and toxicity. J Inorg Biochem 102:532-539.
20. Kumagai Y, Sumi D. 2007. Arsenic: signal transduction, transcription factor, and biotransformation involved in cellular response and toxicity. Annu Rev Pharmacol Toxicol 47:243-262.
21. Lamm SH, Engel A, Penn CA, Chen R, Feinleib M. 2006. Arsenic cancer risk confounder in southwest Taiwan data set. Environ Health Perspect 114:1077-1082.
22. Le XC, Ma M, Cullen WR, Aposhian HV, Lu X, Zheng B. 2000. Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. Environ Health Perspect 108:1015-1018.
23. Lee A, Fraumeni JF Jr. 1969. Arsenic and respiratory cancer in man: an occupational study. J Natl Cancer Inst 42:1045-1052.
24. Lee-Feldstein A. 1983. Arsenic and respiratory cancer in humans - follow-up of copper smelter employees in Montana. J Natl Cancer Inst 70:601-610.
25. Lee-Feldstein A. 1986. Cumulative exposure to arsenic and its relationship to respiratory cancer among copper smelter employees. J Occup Med 28:296-302.
26. Lin S, Cullen WR, Thomas DJ. 1999. Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase. Chem Res Toxicol 12:924-930.
27. Lin S, Del Razo LM, Styblo M, Wang CQ, Cullen WR, Thomas DJ. 2001. Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem Res Toxicol 14:305-311.
28. Lubin JH, Caporaso N. 2006. Cigarette smoking and lung cancer: modeling total exposure and intensity. Cancer Epidemiol Biomarkers Prev 15:517-523.
29. Lubin JH, Pottern LM, Blot WJ, Tokudome S, Stone BJ, Fraumeni JF Jr. 1981. Respiratory cancer among copper smelter workers: recent mortality statistics. J Occup Med 23:779-784.
30. Lubin JH, Pottern LM, Stone BJ, Fraumeni JF. 2000. Respiratory cancer in a cohort of copper smelter workers: results from more than 50 years of follow-up. Am J Epidemiol 151:554-565.
31. Mandal BK, Ogra Y, Suzuki KT. 2001. Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas in West Bengal, India. Chem Res Toxicol 14:371-378.
32. Mass MJ, Tennant A, Roop BC, Cullen WR, Styblo M, Thomas DJ, et al. 2001. Methylated trivalent arsenic species are genotoxic. Chem Res Toxicol 14:355-361.
33. Morris HF. 1978. Testimony on proposed standard for exposure to inorganic arsenic (exhibit 28B) in Department of Labor, Occupational Safety and Health Administration: occupational exposures to inorganic arsenic - final standard. Fed Reg 43:19584-19629.
34. National Research Council. 2006. Health Risks from Exposure to Low Levels of Ionizing Radiation (BEIR VII Phase 2). Washington, DC:National Academy Press.
35. Petrick JS, Jagadish B, Mash EA, Aposhian HV. 2001. Monomethylarsonous acid (MMA(III)) and arsenite: LD50 in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem Res Toxicol 14:651-656.
36. Preston DL, Lubin JH, Pierce DA, McConney ME. 2004. EPICURE: Risk Regression and Data Analysis Software, Release 2.0. Seattle:HiroSoft International Corporation.
37. Pu YS, Yang SM, Huang YK, Chung CJ, Huang SK, Chiu AW, et al. 2007. Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicol Appl Pharmacol 218:99-106.
38. Rahman M, Vahter M, Sohel N, Yunus M, Wahed MA, Streatfield PK, et al. 2006. Arsenic exposure and age- and sex-specific risk for skin lesions: a population-based case-referent study in Bangladesh. Environ Health Perspect 114:1847-1852.
39. Steinmaus C, Bates MN, Yuan Y, Kalman D, Atallah R, Rey OA, et al. 2006. Arsenic methylation and bladder cancer risk in case-control studies in Argentina and the United States. J Occup Environ Med 48:478-488.
40. Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, et al. 2000. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 74:289-299.
41. Styblo M, Drobna Z, Jaspers I, Lin S, Thomas DJ. 2002. The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ Health Perspect 110(suppl 5):767-771.
42. Styblo M, Thomas DJ. 1997. Binding of arsenicals to proteins in an in vitro methylation system. Toxicol Appl Pharmacol 147:1-8.
43. Valenzuela OL, Borja-Aburto VH, Garcia-Vargas GG, Cruz-Gonzalez MB, Garcia-Montalvo EA, Calderon-Aranda ES, et al. 2005. Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ Health Perspect 113:250-254
44. Waters SB, Devesa V, Fricke MW, Creed JT, Styblo M, Thomas DJ. 2004. Glutathione modulates recombinant rat arsenic (+3 oxidation state) methyltransferase-catalyzed formation of trimethylarsine oxide and trimethylarsine. Chem Res Toxicol 17:1621-1629.
45. World Health Organization. 2001. Environmental Health Criteria 224: Arsenic and Arsenic Compounds. 2nd ed. Geneva:World Health Organization.
46. Yu HS, Liao WT, Chai CY. 2006. Arsenic carcinogenesis in the skin. J Biomed Sci 13:657-666.
47. Yu RC, Hsu KH, Chen CJ, Froines JR. 2000. Arsenic methylation capacity and skin cancer. Cancer Epidemiol Biomarkers Prev 9:1259-1262.